Shost:
- Delcath Systems has reported the publication of subgroup analyses from the Phase 3 (FOCUS) study in the Journal of Cancer Research and Clinical Oncology, evaluating the efficacy and safety of the HEPZATO KIT on melphalan/hepatic delivery in pts with unresectable metastatic uveal melanoma
- In the subgroup analyses (n=91) of the P-III (FOCUS) Study pts, with tumor burden below the median had higher ORR (51.1% vs 22.2%) and longer PFS (11.3 vs 5.8 mos.)
- OS was longer with a smaller extent of tumor liver involvement (22.4 vs 16.8 mos.), tumor burden below the median (26.7 vs 15.4 mos.), or low/normal LDH (23.4 vs 15.3 mos.). Of the 33 pts achieving OR, 57.6% responded in 1–2 cycles, 33.3% in Cycles 4–6, supporting the significance of continued treatment up to 6 cycles
Ref: Delcath Systems | Image: Delcath Systems | Press Release
Related News:
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
